Literature DB >> 12548384

Complete deficiency of mitochondrial trifunctional protein due to a novel mutation within the beta-subunit of the mitochondrial trifunctional protein gene leads to failure of long-chain fatty acid beta-oxidation with fatal outcome.

Karl Otfried Schwab1, Regina Ensenauer, Dietrich Matern, Gökhan Uyanik, Birgit Schnieders, Ronald A Wanders, Willy Lehnert.   

Abstract

UNLABELLED: The mitochondrial trifunctional protein (MTP) is a multienzyme complex which catalyses three of the four chain-shortening reactions in the beta-oxidation of long-chain fatty acids. Clinically, failure of long-chain fatty acid beta-oxidation leads to hypoketotic hypoglycaemia associated with coma, hepatopathy, skeletal myopathy and cardiomyopathy. We report on consanguineous parents with six children, four of whom had unexpectedly died in Egypt during the neonatal period due to cardiomyopathy of unknown aetiology and respiratory failure. After moving to Germany, two further children died at the age of 4 months and 12 h, respectively, with signs of respiratory and cardiac failure, hydrops fetalis and acidosis. Analysis of acylcarnitine profiles in dried blood spots of the last two children by electrospray tandem mass spectrometry was indicative of a long-chain fatty acid beta-oxidation disorder. Both infants were homozygous for a novel missense mutation (976G-->C) within a highly conserved region of the MTP beta-subunit gene. Immunoblot analysis in chorionic villi obtained during the subsequent pregnancy demonstrated absence of MTP. In fibroblasts and liver, activities of all three catalytic units of MTP were markedly decreased, further confirming the diagnosis of MTP deficiency.
CONCLUSION: the detected mutation (976G-->C) within the beta-subunit of the mitochondrial trifunctional protein gene destabilises the protein, leading to complete deficiency and a poor prognosis. Immunoblot analysis of mitochondrial trifunctional protein in chorionic villi may be a valuable tool for the prenatal diagnosis of the disorder when the molecular genetic defect is unknown.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548384     DOI: 10.1007/s00431-002-1035-4

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  4 in total

Review 1.  Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management.

Authors:  Prem S Shekhawat; Dietrich Matern; Arnold W Strauss
Journal:  Pediatr Res       Date:  2005-04-06       Impact factor: 3.756

2.  Fatty acid oxidation in the human fetus: implications for fetal and adult disease.

Authors:  Nadia A Oey; Jos P N Ruiter; Tania Attié-Bitach; Lodewijk Ijlst; Ronald J A Wanders; Frits A Wijburg
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

3.  Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids.

Authors:  Hiroshi Irie; Irvin B Krukenkamp; Joep F F Brinkmann; Glenn R Gaudette; Adam E Saltman; William Jou; Jan F C Glatz; Nada A Abumrad; Azeddine Ibrahimi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

4.  A compound heterozygous mutation in HADHB gene causes an axonal Charcot-Marie-tooth disease.

Authors:  Young Bin Hong; Ja Hyun Lee; Jin-Mo Park; Yu-Ri Choi; Young Se Hyun; Bo Ram Yoon; Jeong Hyun Yoo; Heasoo Koo; Sung-Chul Jung; Ki Wha Chung; Byung-Ok Choi
Journal:  BMC Med Genet       Date:  2013-12-05       Impact factor: 2.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.